skip to main content

Hypercalcaemia with Renal Impairment — RACP Adult Medicine MCQ

Instant feedback + full explanation. One question, done properly.

HardClinical PharmacologyHypercalcaemia with Renal ImpairmentRACP Adult Medicine

A 55-year-old woman with breast cancer develops acute confusion, lethargy, and a calcium of 3.6 mmol/L. She is severely dehydrated with a creatinine of 200 µmol/L. After adequate IV fluid resuscitation and calcitonin, what bisphosphonate is most appropriate and why?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: EDenosumab – as bisphosphonates are contraindicated with creatinine >200

With significant renal impairment (creatinine 200 µmol/L), bisphosphonates require dose adjustment or are relatively contraindicated (zoledronic acid is not recommended with CrCl <35 mL/min). Denosumab (a RANKL inhibitor) does not require renal dose adjustment and is effective for malignancy-associated hypercalcaemia refractory to bisphosphonates or when bisphosphonates are contraindicated by renal impairment. However, calcium monitoring is essential as denosumab can cause severe hypocalcaemia in CKD.

Reference: AMH – 2025 – Bone Modifying Agents; eTG – 2025 – Endocrinology